

Eitan Amir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4170361/publications.pdf>

Version: 2024-02-01

341
papers

16,148
citations

26630
56
h-index

20961
115
g-index

344
all docs

344
docs citations

344
times ranked

23954
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2014, 106, dju124.	6.3	2,202
2	Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2012, 30, 1934-1940.	1.6	602
3	Delivering affordable cancer care in high-income countries. Lancet Oncology, The, 2011, 12, 933-980.	10.7	571
4	Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2011, 103, 1299-1309.	6.3	538
5	Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1204-1212.	2.5	519
6	Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Research, 2017, 19, 2.	5.0	457
7	PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. Cell Metabolism, 2015, 22, 577-589.	16.2	430
8	Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models. Journal of the National Cancer Institute, 2010, 102, 680-691.	6.3	413
9	Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer. Journal of Clinical Oncology, 2012, 30, 587-592.	1.6	377
10	Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2014, 106, djt319-djt319.	6.3	279
11	Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. Journal of Medical Genetics, 2003, 40, 807-814.	3.2	261
12	A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. Journal of Medical Genetics, 2004, 41, 474-480.	3.2	232
13	A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer. JAMA Cardiology, 2017, 2, 88.	6.1	232
14	Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. American Journal of Pathology, 2009, 175, 808-816.	3.8	223
15	Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treatment Reviews, 2017, 53, 120-127.	7.7	178
16	HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis. Journal of the National Cancer Institute, 2013, 105, 266-273.	6.3	168
17	Systemic Therapy for Non-clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis. European Urology, 2015, 67, 740-749.	1.9	166
18	Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treatment Reviews, 2012, 38, 708-714.	7.7	153

#	ARTICLE	IF	CITATIONS
19	The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs. Journal of Clinical Oncology, 2012, 30, 3012-3019.	1.6	152
20	Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e95219.	2.5	140
21	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. European Urology, 2016, 70, 358-364.	1.9	133
22	Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. Journal of the American Heart Association, 2017, 6, .	3.7	130
23	Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 31-39.	6.3	129
24	Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer, 2014, 120, 3346-3352.	4.1	128
25	Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study. Journal of Clinical Oncology, 2016, 34, 2239-2246.	1.6	125
26	Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. European Journal of Cancer, 2014, 50, 1581-1589.	2.8	119
27	Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Annals of Oncology, 2015, 26, 743-749.	1.2	119
28	Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Annals of Oncology, 2013, 24, 2972-2977.	1.2	117
29	Mismatch repair status and clinical outcome in endometrial cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2013, 88, 154-167.	4.4	113
30	Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. , 2020, 8, e000467.		106
31	Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Annals of Oncology, 2013, 24, 1238-1244.	1.2	104
32	Biosimilars of Biological Drug Therapies. Drugs, 2011, 71, 1527-1536.	10.9	101
33	Claudin-2 Promotes Breast Cancer Liver Metastasis by Facilitating Tumor Cell Interactions with Hepatocytes. Molecular and Cellular Biology, 2012, 32, 2979-2991.	2.3	89
34	Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Research and Treatment, 2013, 139, 603-606.	2.5	86
35	Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecologic Oncology, 2017, 145, 584-594.	1.4	85
36	Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?. European Journal of Cancer, 2012, 48, 385-388.	2.8	84

#	ARTICLE	IF	CITATIONS
37	Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 727-736.	6.3	84
38	Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 4260-4267.	1.6	83
39	Association of the Timing of Pregnancy With Survival in Women With Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 659.	7.1	82
40	Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. <i>Journal of Medical Genetics</i> , 2009, 46, 811-817.	3.2	80
41	Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors: Similar Results but Different Conclusions. <i>Journal of Clinical Oncology</i> , 2011, 29, 254-256.	1.6	80
42	Importance of Considering Competing Risks in Time-to-Event Analyses. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004580.	2.2	80
43	Under-reporting of harm in clinical trials. <i>Lancet Oncology</i> , The, 2016, 17, e209-e219.	10.7	76
44	Relevance of randomised controlled trials in oncology. <i>Lancet Oncology</i> , The, 2016, 17, e560-e567.	10.7	74
45	Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 235-244.	2.5	73
46	Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2017, 147, 158-166.	1.4	71
47	Failures in Phase III: Causes and Consequences. <i>Clinical Cancer Research</i> , 2015, 21, 4552-4560.	7.0	70
48	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , 2018, 110, 486-492.	6.3	70
49	Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 62, 1-8.	7.7	69
50	Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma—a meta-analysis. <i>European Journal of Cancer</i> , 2018, 105, 1-9.	2.8	69
51	Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. <i>Journal of Geriatric Oncology</i> , 2014, 5, 119-126.	1.0	68
52	The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. <i>European Journal of Cancer</i> , 2016, 68, 11-21.	2.8	65
53	Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs. <i>Journal of Clinical Oncology</i> , 2011, 29, 2543-2549.	1.6	64
54	Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3634-3642.	1.6	64

#	ARTICLE	IF	CITATIONS
55	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treatment Reviews, 2020, 89, 102084.	7.7	61
56	Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. European Heart Journal, 2019, 40, 3913-3920.	2.2	60
57	A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D ₃ in breast cancer patients with bone metastases. Cancer, 2010, 116, 284-291.	4.1	59
58	Discordance between Receptor Status in Primary and Metastatic Breast Cancer: an Exploratory Study of Bone and Bone Marrow Biopsies. Clinical Oncology, 2008, 20, 763-768.	1.4	57
59	CCN3 Impairs Osteoblast and Stimulates Osteoclast Differentiation to Favor Breast Cancer Metastasis to Bone. American Journal of Pathology, 2011, 178, 2377-2388.	3.8	54
60	Halitosis in children. Journal of Pediatrics, 1999, 134, 338-343.	1.8	53
61	Cost-effectiveness of Outpatient Management for Febrile Neutropenia in Children With Cancer. Pediatrics, 2011, 127, e279-e286.	2.1	53
62	Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. Scientific Reports, 2017, 7, 17530.	3.3	53
63	HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates. Breast Cancer Research, 2020, 22, 15.	5.0	53
64	Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions. Cancer Treatment Reviews, 2009, 35, 685-691.	7.7	52
65	Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. European Journal of Cancer, 2017, 77, 40-47.	2.8	52
66	Targeting DNA repair in breast cancer: A clinical and translational update. Cancer Treatment Reviews, 2010, 36, 557-565.	7.7	51
67	25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Research and Treatment, 2012, 133, 1077-1088.	2.5	51
68	Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis. PLoS ONE, 2014, 9, e88238.	2.5	51
69	Large Retroperitoneal Lymphadenopathy As a Predictor of Venous Thromboembolism in Patients With Disseminated Germ Cell Tumors Treated With Chemotherapy. Journal of Clinical Oncology, 2015, 33, 582-587.	1.6	50
70	Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity. Heart, 2020, 106, 817-823.	2.9	50
71	Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer. JACC: Cardiovascular Imaging, 2021, 14, 962-974.	5.3	50
72	Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. Journal of the National Cancer Institute, 2021, 113, 1465-1475.	6.3	50

#	ARTICLE	IF	CITATIONS
73	The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study. Journal of the National Cancer Institute, 2019, 111, 854-862.	6.3	49
74	Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Canadian Journal of Cardiology, 2019, 35, 153-159.	1.7	49
75	Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis. Clinical Cancer Research, 2012, 18, 4526-4537.	7.0	48
76	Author Financial Conflicts of Interest, Industry Funding, and Clinical Practice Guidelines for Anticancer Drugs. Journal of Clinical Oncology, 2015, 33, 100-106.	1.6	47
77	Statin Exposure and Risk of Heart Failure After Anthracycline or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score-Matched Cohort Study. Journal of the American Heart Association, 2021, 10, e018393.	3.7	47
78	p53 Arg72Pro Polymorphism, HPV Status and Initiation, Progression, and Development of Cervical Cancer: A Systematic Review and Meta-Analysis. Clinical Cancer Research, 2012, 18, 6407-6415.	7.0	46
79	Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Research and Treatment, 2011, 129, 761-765.	2.5	44
80	Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: A systematic review and meta-analysis. Cancer Treatment Reviews, 2018, 69, 1-10.	7.7	44
81	Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy. Journal of Oncology, 2015, 2015, 1-10.	1.3	43
82	Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis. Annals of Oncology, 2017, 28, 628-633.	1.2	43
83	Role of Bisphosphonates in Breast Cancer Therapy. Current Treatment Options in Oncology, 2019, 20, 26.	3.0	43
84	Informative censoring – a neglected cause of bias in oncology trials. Nature Reviews Clinical Oncology, 2020, 17, 327-328.	27.6	43
85	Bias in reporting of randomised clinical trials in oncology. European Journal of Cancer, 2016, 61, 29-35.	2.8	42
86	Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treatment Reviews, 2017, 56, 1-7.	7.7	42
87	Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2019, 175, 531-545.	2.5	42
88	Clinical trial design in biosimilar drug development. Investigational New Drugs, 2013, 31, 479-487.	2.6	41
89	Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. PLoS ONE, 2015, 10, e0132449.	2.5	41
90	ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. Breast Cancer Research, 2012, 14, R149.	5.0	40

#	ARTICLE	IF	CITATIONS
91	A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229). <i>Oncologist</i> , 2019, 24, 1439-1445.	3.7	40
92	The Effect of Exercise on Quality of Life, Fatigue, Physical Function, and Safety in Advanced Solid Tumor Cancers: A Meta-analysis of Randomized Control Trials. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 899-908.e7.	1.2	40
93	Physiologic pigmentation of the oral mucosa in Israeli children. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1991, 71, 396-398.	0.6	39
94	Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 609-617.	2.5	39
95	Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study. <i>Supportive Care in Cancer</i> , 2017, 25, 879-886.	2.2	39
96	Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1040.	2.8	38
97	Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2980-2987.	1.6	37
98	Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?. <i>Lancet Oncology</i> , The, 2009, 10, 933-935.	10.7	36
99	Outcome of Adjuvant Therapy in Biliary Tract Cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 382-387.	1.3	36
100	Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting. <i>Journal of Clinical Oncology</i> , 2016, 34, 1469-1475.	1.6	36
101	PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2019, 76, 51-56.	7.7	36
102	Pharmacogenetic and Germline Prognostic Markers of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 296-304.	1.1	35
103	Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2014, 40, 1048-1055.	7.7	34
104	Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome. <i>Oncolimmunology</i> , 2019, 8, e1629780.	4.6	34
105	Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 951-962.	5.3	34
106	How valid are claims for synergy in published clinical studies?. <i>Annals of Oncology</i> , 2012, 23, 2161-2166.	1.2	33
107	Randomized Feasibility Study of De-escalated (Every 12 wk) Versus Standard (Every 3 to 4 wk) Intravenous Pamidronate in Women With Low-risk Bone Metastases From Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 436-442.	1.3	33
108	Cardiac Outcomes in Survivors of Pediatric and Adult Cancers. <i>Canadian Journal of Cardiology</i> , 2016, 32, 871-880.	1.7	33

#	ARTICLE	IF	CITATIONS
109	Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: A systematic review. <i>Gynecologic Oncology</i> , 2012, 124, 354-365.	1.4	32
110	Tumor-Infiltrating Lymphocytes in Breast Cancer: Ready for Prime Time?. <i>Journal of Clinical Oncology</i> , 2015, 33, 1298-1299.	1.6	32
111	A randomized phase II trial of geriatric assessment and management for older cancer patients. <i>Supportive Care in Cancer</i> , 2018, 26, 109-117.	2.2	32
112	Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. <i>British Journal of Cancer</i> , 2011, 104, 1377-1383.	6.4	31
113	Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. <i>PLoS ONE</i> , 2016, 11, e0154789.	2.5	31
114	Benefit and Harms of New Anti-Cancer Drugs. <i>Current Oncology Reports</i> , 2013, 15, 270-275.	4.0	30
115	Circulating DNA and Survival in Solid Tumors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 399-406.	2.5	30
116	Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines. <i>Cancer</i> , 2019, 125, 4069-4075.	4.1	30
117	Fulvestrant for advanced breast cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2013, 39, 753-758.	7.7	29
118	Does a dedicated program for young breast cancer patients affect the likelihood of fertility preservation discussion and referral?. <i>Breast</i> , 2016, 27, 22-26.	2.2	29
119	Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 90, 102086.	7.7	29
120	An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2011, 22, 1805-1811.	1.2	28
121	Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies. <i>Cancer Treatment Reviews</i> , 2016, 43, 67-73.	7.7	28
122	Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2018, 30, 215-224.	1.4	28
123	Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors. <i>PLoS ONE</i> , 2017, 12, e0175128.	2.5	28
124	Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 935-943.	3.3	27
125	Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, 410-415.	7.7	27
126	Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. <i>Supportive Care in Cancer</i> , 2011, 19, 1687-1696.	2.2	27

#	ARTICLE	IF	CITATIONS
127	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 168, 159-168.	2.5	27
128	Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials. Journal of Clinical Oncology, 2018, 36, 1798-1804.	1.6	27
129	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials. JAMA Oncology, 2018, 4, 1610.	7.1	27
130	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget, 2015, 6, 39538-39549.	1.8	27
131	A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. Breast Cancer Research and Treatment, 2014, 144, 615-624.	2.5	25
132	Dose-dense treatment for triple-negative breast cancer. Nature Reviews Clinical Oncology, 2010, 7, 79-80.	27.6	24
133	Honorary and ghost authorship in reports of randomised clinical trials in oncology. European Journal of Cancer, 2016, 66, 1-8.	2.8	23
134	Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancerâ€”the 5C study: a study protocol for a randomised controlled phase III trial. BMJ Open, 2019, 9, e024485.	1.9	23
135	Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies.. Journal of Clinical Oncology, 2010, 28, 1007-1007.	1.6	22
136	Advances in Cancer Therapeutics and Patient Access to New Drugs. Pharmacoeconomics, 2011, 29, 213-224.	3.3	21
137	Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept. Clinical Cancer Research, 2013, 19, 4931-4940.	7.0	21
138	Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials. Cancer Treatment Reviews, 2016, 45, 1-6.	7.7	21
139	Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. Cancer Treatment Reviews, 2017, 60, 53-59.	7.7	21
140	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2017, 18, 909.	4.1	21
141	Outcomes of single versus double hormone receptorâ€”positive breast cancer. A GEICAM/9906 sub-study. European Journal of Cancer, 2018, 94, 199-205.	2.8	21
142	Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3369-3379.	2.5	21
143	<i>In silico</i> analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. Oncotarget, 2016, 7, 22865-22872.	1.8	21
144	Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies. Oncotarget, 2016, 7, 45042-45051.	1.8	21

#	ARTICLE	IF	CITATIONS
145	Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study. American Journal of Kidney Diseases, 2022, 80, 436-448.e1.	1.9	21
146	The evolving landscape of protein kinases in breast cancer: Clinical implications. Cancer Treatment Reviews, 2013, 39, 68-76.	7.7	20
147	Association of Aromatase Inhibitors With Coronary Heart Disease in Women With Early Breast Cancer. Cancer Investigation, 2014, 32, 99-104.	1.3	20
148	Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. JNCI Cancer Spectrum, 2019, 3, pkz033.	2.9	20
149	Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 374-387.	3.8	19
150	Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. Cancer, 2020, 126, 4390-4399.	4.1	19
151	Prevalence of Overt Metastases in Locally Advanced Breast Cancer. Clinical Oncology, 2008, 20, 340-344.	1.4	18
152	Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases. Clinical and Experimental Metastasis, 2009, 26, 479-484.	3.3	18
153	Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. SpringerPlus, 2014, 3, 577.	1.2	18
154	Association Between Data Sources and US Food and Drug Administration Drug Safety Communications. JAMA Internal Medicine, 2019, 179, 1590.	5.1	18
155	Association of Early-Stage Breast Cancer and Subsequent Chemotherapy With Risk of Atrial Fibrillation. JAMA Network Open, 2019, 2, e1911838.	5.9	18
156	The Impact of Big Data Research on Practice, Policy, and Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e167-e175.	3.8	18
157	Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations. Cancer Medicine, 2019, 8, 1584-1593.	2.8	18
158	Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. Oncotarget, 2017, 8, 21733-21740.	1.8	18
159	Defining ovarian failure in amenorrheic young breast cancer patients. Breast, 2010, 19, 545-548.	2.2	17
160	Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting. Journal of Bone Oncology, 2015, 4, 54-58.	2.4	17
161	Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy—a survey of health care providers and patients. Supportive Care in Cancer, 2015, 23, 3269-3275.	2.2	17
162	Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration. JAMA Oncology, 2016, 2, 744.	7.1	17

#	ARTICLE	IF	CITATIONS
163	Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression. <i>Experimental and Molecular Pathology</i> , 2017, 102, 455-474.	2.1	17
164	Refining Early Antitumoral Drug Development. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 922-925.	8.7	17
165	Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). <i>Cancer Medicine</i> , 2020, 9, 116-124.	2.8	17
166	Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091529.	3.2	17
167	Impact of Cancer Therapy-Related Cardiac Dysfunction on Risk of Heart Failure in Pregnancy. <i>JACC: CardioOncology</i> , 2020, 2, 153-162.	4.0	17
168	Influence of censoring on conclusions of trials for women with metastatic breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 721-724.	2.8	16
169	Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) – A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 63, 71-78.	7.7	16
170	Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors. <i>PLoS ONE</i> , 2019, 14, e0209134.	2.5	16
171	Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. <i>Npj Breast Cancer</i> , 2021, 7, 77.	5.2	16
172	A Combined Echocardiography Approach for the Diagnosis of Cancer Therapy-Related Cardiac Dysfunction in Women With Early-Stage Breast Cancer. <i>JAMA Cardiology</i> , 2022, 7, 330.	6.1	16
173	Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. <i>Annals of Oncology</i> , 2012, 23, 2977-2982.	1.2	15
174	Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers. <i>Journal of Bone Oncology</i> , 2013, 2, 154-157.	2.4	15
175	Birth-Weight, Pregnancy Term, Pre-Natal and Natal Complications Related to Child's Dental Anomalies. <i>Journal of Clinical Pediatric Dentistry</i> , 2015, 39, 371-376.	1.0	15
176	Toward Value-Based Pricing to Boost Cancer Research and Innovation. <i>Cancer Research</i> , 2016, 76, 3127-3129.	0.9	15
177	Prevention, Detection, and Management of Chemotherapy-Related Cardiac Dysfunction. <i>Canadian Journal of Cardiology</i> , 2016, 32, 891-899.	1.7	15
178	A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 155-161.	2.5	14
179	Management of small HER2 overexpressing tumours. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 289-293.	2.5	14
180	Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study. <i>PLoS ONE</i> , 2015, 10, e0122735.	2.5	14

#	ARTICLE	IF	CITATIONS
181	Economic Evaluation of Hormonal Therapies for Postmenopausal Women with Estrogen Receptor-Positive Early Breast Cancer in Canada. <i>Current Oncology</i> , 2015, 22, 84-96.	2.2	14
182	Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer. <i>Cancer Medicine</i> , 2018, 7, 1896-1907.	2.8	14
183	Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 413-425.	2.5	14
184	Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results. <i>Oncotarget</i> , 2018, 9, 31915-31919.	1.8	14
185	Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2019, 77, 11-19.	7.7	14
186	Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer. <i>American Journal of Cardiology</i> , 2020, 125, 1270-1275.	1.6	14
187	Modified Routine Cardiac Imaging Surveillance of Adult Cancer Patients and Survivors During the COVID-19 Pandemic. <i>JACC: CardioOncology</i> , 2020, 2, 345-349.	4.0	14
188	Benefits and Harms of Detecting Clinically Occult Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1542-1547.	6.3	13
189	Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e193-e199.	1.9	13
190	A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 875-883.	0.9	13
191	A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. <i>European Urology Focus</i> , 2021, 7, 1130-1136.	3.1	13
192	Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102283.	7.7	13
193	Do We Have to Change the Way Targeted Drugs Are Developed?. <i>Journal of Clinical Oncology</i> , 2010, 28, e420-e421.	1.6	12
194	A critique of the fragility index. <i>Lancet Oncology</i> , The, 2019, 20, e552.	10.7	12
195	Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, e212140.	7.1	12
196	Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. <i>Journal of Surgical Oncology</i> , 2019, 119, 932-940.	1.7	11
197	Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV. <i>JAMA Network Open</i> , 2019, 2, e1914816.	5.9	11
198	General Overview and Treatment Recommendations for Young Women with Breast Cancer. <i>Revista De Investigacion Clinica</i> , 2017, 69, 77-93.	0.4	11

#	ARTICLE	IF	CITATIONS
199	Zoledronic acid for breast cancer therapy-induced bone loss. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 187-188.	27.6	10
200	Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 267-279.	2.5	10
201	A Matched Cohort Study of Patients With End-Stage Heart Failure from Anthracycline-Induced Cardiomyopathy Requiring Advanced Cardiac Support. <i>American Journal of Cardiology</i> , 2016, 118, 1539-1544.	1.6	10
202	Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 1-8.	2.5	10
203	Fertility preservation in post-pubescent female cancer patients: A practical guideline for clinicians. <i>Molecular and Clinical Oncology</i> , 2017, 8, 153-158.	1.0	10
204	Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. <i>Clinical and Translational Oncology</i> , 2018, 20, 1548-1556.	2.4	10
205	Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky028.	2.9	10
206	Health status, emergency department visits, and oncologists' feedback: An analysis of secondary endpoints from a randomized phase II geriatric assessment trial. <i>Journal of Geriatric Oncology</i> , 2019, 10, 169-174.	1.0	10
207	Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2019, 2, 448-455.	5.4	10
208	Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials. <i>Mayo Clinic Proceedings</i> , 2019, 94, 74-83.	3.0	10
209	Amenorrhoea, menopause, and endocrine therapy for breast cancer. <i>BMJ: British Medical Journal</i> , 2009, 339, b4261-b4261.	2.3	10
210	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. <i>Current Oncology</i> , 2021, 28, 107-114.	2.2	10
211	Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy. <i>JACC: CardioOncology</i> , 2021, 3, 678-691.	4.0	10
212	Altered calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer. <i>Anticancer Research</i> , 2009, 29, 2707-11.	1.1	10
213	Clinical Research: Show Us the Data. <i>Journal of Clinical Oncology</i> , 2011, 29, 1099-1100.	1.6	9
214	Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS). <i>Journal of Bone Oncology</i> , 2016, 5, 57-62.	2.4	9
215	Determinants of the recommended phase 2 dose of molecular targeted agents. <i>Cancer</i> , 2017, 123, 1409-1415.	4.1	9
216	Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 71, 68-75.	7.7	9

#	ARTICLE	IF	CITATIONS
217	Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer. Breast Cancer Research and Treatment, 2018, 172, 725-732.	2.5	9
218	Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. Cancer Treatment Reviews, 2018, 70, 138-143.	7.7	9
219	Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation. International Journal of Radiation Oncology Biology Physics, 2020, 108, 676-685.	0.8	9
220	Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers. Journal of Cancer, 2021, 12, 4372-4378.	2.5	9
221	Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer. Journal of Clinical Pathology, 2009, 62, 474-476.	2.0	8
222	Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. Breast Cancer Research and Treatment, 2009, 118, 377-383.	2.5	8
223	Aromatase inhibitors for prevention of breast cancer in postmenopausal women. Menopause, 2015, 22, 342-350.	2.0	8
224	Impact of the Pan-Canadian Oncology Drug Review on Provincial Concordance with Respect to Cancer Drug Funding Decisions and Time to Funding. Current Oncology, 2017, 24, 295-301.	2.2	8
225	Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours. Cancer Treatment Reviews, 2021, 94, 102167.	7.7	8
226	Characteristics and Outcomes of Women Developing Heart Failure After Early Stage Breast Cancer Chemotherapy: A Population-Based Matched Cohort Study. Circulation: Heart Failure, 2021, 14, e008110.	3.9	8
227	Antivascular agents for non-small-cell lung cancer: current status and future directions. Expert Opinion on Investigational Drugs, 2009, 18, 1667-1686.	4.1	7
228	Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. Supportive Care in Cancer, 2011, 19, 315-322.	2.2	7
229	Demystifying the role of tumor HPV status in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology, 2014, 25, 760-762.	1.2	7
230	Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel. Radiology and Oncology, 2015, 49, 402-408.	1.7	7
231	The Voices of Young Women with Breast Cancer: Providing Support and Information for Improved Fertility Preservation Discussions. Journal of Adolescent and Young Adult Oncology, 2019, 8, 547-553.	1.3	7
232	Undisclosed Financial Conflicts of Interest of Authors of Clinical Drug Trials Published in Influential Medical Journals: A Cohort Study. Mayo Clinic Proceedings, 2019, 94, 2272-2276.	3.0	7
233	Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. Npj Breast Cancer, 2020, 6, 22.	5.2	7
234	Influence of Competing Risks on Estimates of Recurrence Risk and Breast Cancer-specific Mortality in Analyses of the Early Breast Cancer Trialists Collaborative Group. Scientific Reports, 2020, 10, 4091.	3.3	7

#	ARTICLE	IF	CITATIONS
235	Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. <i>European Journal of Cancer</i> , 2021, 149, 117-127.	2.8	7
236	Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110726.	3.2	7
237	Mandibular Block or Maxillary Infiltration. <i>Journal of Clinical Pediatric Dentistry</i> , 2012, 36, 245-250.	1.0	6
238	Does estrogen play a role in response to adjuvant bone-targeted therapies?. <i>Journal of Bone Oncology</i> , 2013, 2, 167-173.	2.4	6
239	Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 839-843.	2.0	6
240	The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 307-313.	3.8	6
241	Rethinking end-points for bone-targeted therapy in Advanced cancer. <i>European Journal of Cancer</i> , 2016, 63, 105-109.	2.8	6
242	Integrin $\alpha_2\beta_6$ Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 143-151.	3.8	6
243	A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane-associated pain syndrome (TAPS) in breast cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 5787-5795.	2.2	6
244	Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 847.	2.4	6
245	Absolute Benefits of Aromatase Inhibitors in Adjuvant Treatment of Breast Cancer: Should We Know More?. <i>Journal of Clinical Oncology</i> , 2010, 28, e346-e347.	1.6	5
246	Dual Blockade of HER2 " Twice as Good or Twice as Toxic?. <i>Clinical Oncology</i> , 2012, 24, 593-603.	1.4	5
247	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 295-307.	5.9	5
248	Bone-targeted therapy for metastatic breast cancer"Where do we go from here? A commentary from the BONUS 8 meeting. <i>Journal of Bone Oncology</i> , 2014, 3, 1-4.	2.4	5
249	Efficacy-effectiveness gap as an obstacle to translating clinical trials to clinical practice. <i>European Journal of Cancer</i> , 2015, 51, 905-906.	2.8	5
250	Left Ventricular Dysfunction With Trastuzumab Therapy: Is Primary Prevention the Best Option?. <i>Journal of Clinical Oncology</i> , 2017, 35, 820-825.	1.6	5
251	Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals. <i>European Journal of Internal Medicine</i> , 2020, 71, 45-49.	2.2	5
252	Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors. <i>Cancer Medicine</i> , 2020, 9, 7888-7895.	2.8	5

#	ARTICLE	IF	CITATIONS
253	Treatment-related side effects as predictors of efficacy of check-point inhibitors (CPIs).. Journal of Clinical Oncology, 2016, 34, 3062-3062.	1.6	5
254	The Impact of Cognitive Impairment on Treatment Toxicity, Treatment Completion, and Survival among Older Adults Receiving Chemotherapy: A Systematic Review. Cancers, 2022, 14, 1582.	3.7	5
255	Underestimation of Risk by Gail Model Extends Beyond Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2009, 27, 1526-1526.	1.6	4
256	Treatment Recommendations for the Use of Bone-Targeted Agents in 2011 Report from the 6th Annual Bone and the Oncologist New Updates Meeting. Current Oncology, 2012, 19, 364-370.	2.2	4
257	Human papillomavirus and host genetic polymorphisms in carcinogenesis: A systematic review and meta-analysis. Journal of Clinical Virology, 2014, 61, 220-229.	3.1	4
258	One step forward, two steps back: The story of everolimus in advanced breast cancer. Breast, 2015, 24, 529-531.	2.2	4
259	Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs. Molecular Diagnosis and Therapy, 2017, 21, 337-343.	3.8	4
260	National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. Cancer Treatment Reviews, 2020, 91, 102113.	7.7	4
261	The Yield of Routine Cardiac Imaging in Breast Cancer Patients Receiving Trastuzumab-Based Treatment: A Retrospective Cohort Study. Canadian Journal of Cardiology, 2020, 36, 1658-1666.	1.7	4
262	Feasibility randomised controlled trial of remote symptom chemotherapy toxicity monitoring using the Canadian adapted Advanced Symptom Management System (ASyMS-Can): a study protocol. BMJ Open, 2020, 10, e035648.	1.9	4
263	Resource stratified guidelines for cancer: Are they all the same? Interguideline concordance for systemic treatment recommendations. International Journal of Cancer, 2022, 150, 91-99.	5.1	4
264	Patient and provider determinants of breast cancer screening among Ontario women aged 40-49: a population-based retrospective cohort study. Breast Cancer Research and Treatment, 2021, 189, 631-640.	2.5	4
265	Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 117-125.	4.9	4
266	Androgen deprivation therapy and bone loss. Nature Reviews Urology, 2009, 6, 642-644.	3.8	3
267	Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?. Critical Reviews in Oncology/Hematology, 2009, 72, 56-64.	4.4	3
268	Biopsy confirmation of metastatic breast cancer: interim results of a prospective biopsy study. Breast Cancer Research, 2009, 11, .	5.0	3
269	Breast Cancer Chemoprevention Gets Personal. Journal of Clinical Oncology, 2011, 29, 2296-2298.	1.6	3
270	The use of myocardial strain and newer echocardiography imaging techniques in cancer patients. Future Oncology, 2015, 11, 2035-2041.	2.4	3

#	ARTICLE	IF	CITATIONS
271	Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. <i>Clinical Oncology</i> , 2016, 28, 283-291.	1.4	3
272	Assisting with Decision-Making: How Standardized Information Impacts Breast Cancer Patient Decisions Regarding Fertility Trade-Offs and Chemotherapy. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 660-667.	1.3	3
273	Competing risks of extended adjuvant aromatase inhibitors. <i>Lancet Oncology</i> , The, 2019, 20, 8-9.	10.7	3
274	Pembrolizumab monotherapy in metastatic triple-negative breast cancer. <i>Lancet Oncology</i> , The, 2021, 22, 415-417.	10.7	3
275	Are NCCN Resource-Stratified Guidelines for Breast Cancer Systemic Therapy Achievable? A Population-Based Study of Global Need and Economic Impact. <i>JCO Global Oncology</i> , 2021, 7, 1074-1083.	1.8	3
276	The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102293.	7.7	3
277	A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 70-70.	1.6	3
278	Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 101, 102299.	7.7	3
279	A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time. <i>Scientific Reports</i> , 2022, 12, 6352.	3.3	3
280	Lapatinib Plus Paclitaxel As First-Line Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer: Inappropriate Conclusions From a Company-Sponsored Study?. <i>Journal of Clinical Oncology</i> , 2009, 27, 1919-1919.	1.6	2
281	Multidimensional Challenges in Clinical Drug Development, Regulatory Approval, and Marketing. <i>Journal of Clinical Oncology</i> , 2013, 31, 1252-1253.	1.6	2
282	Raising Concern About the American Society of Clinical Oncology Conflict of Interest Policy Amendment. <i>Journal of Clinical Oncology</i> , 2014, 32, 3197-3197.	1.6	2
283	Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2017, 59, 46-53.	7.7	2
284	EQUATOR-Oncology: reducing the latitude of cancer trial design and reporting. <i>British Journal of Cancer</i> , 2018, 118, 617-618.	6.4	2
285	Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual. <i>JAMA Oncology</i> , 2019, 5, 107.	7.1	2
286	Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis. <i>European Urology Open Science</i> , 2020, 21, 61-68.	0.4	2
287	Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations. <i>Cancer Medicine</i> , 2021, 10, 5405-5414.	2.8	2
288	Adjuvant Zoledronate Therapy for Women With Breast Cancerâ€“Effective Treatment or Foolâ€™s Gold?. <i>JAMA Oncology</i> , 2021, 7, 1121.	7.1	2

#	ARTICLE	IF	CITATIONS
289	Association between pretreatment neutrophil to lymphocyte ratio (NLR) and complete pathological response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NACT).. Journal of Clinical Oncology, 2015, 33, e11588-e11588.	1.6	2
290	Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2018, 36, 1094-1094.	1.6	2
291	Absolute benefit from adjuvant chemotherapy in triple negative breast cancer (TNBC): A systemic review and meta-analysis.. Journal of Clinical Oncology, 2018, 36, e12501-e12501.	1.6	2
292	Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1433-1440.	4.9	2
293	Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies. Cancer Treatment Reviews, 2021, 101, 102310.	7.7	2
294	Bias in reporting of endpoints of efficacy and toxicity in randomized clinical trials (RCTs) for women with breast cancer (BC).. Journal of Clinical Oncology, 2012, 30, 6043-6043.	1.6	2
295	A feasibility trial of geriatric assessment and integrated care plan for older cancer patients.. Journal of Clinical Oncology, 2016, 34, 10054-10054.	1.6	2
296	Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer. Oncotarget, 2018, 9, 15061-15067.	1.8	2
297	Feasibility of a Remotely Delivered Strength and Balance Training Program for Older Adults with Cancer. Current Oncology, 2021, 28, 4408-4419.	2.2	2
298	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. Molecular Diagnosis and Therapy, 2022, , 1.	3.8	2
299	Clinical benefit of cancer drugs approved in Switzerland 2010â€“2019. PLoS ONE, 2022, 17, e0268545.	2.5	2
300	1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer. European Journal of Cancer, 2015, 51, S176-S177.	2.8	1
301	Pathological complete response in breast cancer. Lancet, The, 2015, 385, 113.	13.7	1
302	Response. Journal of the National Cancer Institute, 2015, 107, djv244.	6.3	1
303	Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer. Current Oncology Reports, 2017, 19, 15.	4.0	1
304	Reporting of Randomized Trials in Common Cancers in the Lay Media. Oncology, 2018, 94, 65-71.	1.9	1
305	Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S995-S998.	1.4	1
306	Expedited approval of cancer drugs without randomized controlled trials: Too good to be true?. Oncotarget, 2018, 9, 30942-30943.	1.8	1

#	ARTICLE	IF	CITATIONS
307	Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade. Scientific Reports, 2021, 11, 10843.	3.3	1
308	Abstract P3-13-05: Evaluating efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events. TRIUMPH: A pragmatic multicentre trial.. , 2012, , .		1
309	Abstract P2-08-05: Association between the neutrophil-to-lymphocyte ratio (NLR) and the 21-gene recurrence score. , 2016, , .		1
310	Abstract P4-14-03: Influence of competing risks of death on the interpretation of adjuvant endocrine therapy trials for breast cancer. , 2019, , .		1
311	The balance between benefits and harms of molecular targeted agents.. Journal of Clinical Oncology, 2011, 29, 6030-6030.	1.6	1
312	Forty years of randomized trials in advanced/metastatic soft tissue sarcoma (STS): Endpoint selection, surrogacy and quality of reporting.. Journal of Clinical Oncology, 2015, 33, 10513-10513.	1.6	1
313	Toxicity of extended adjuvant aromatase inhibitors therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2017, 35, 549-549.	1.6	1
314	Outcomes of single versus double hormone receptor positive breast cancer.. Journal of Clinical Oncology, 2016, 34, 569-569.	1.6	1
315	Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.. Journal of Clinical Oncology, 2017, 35, e18336-e18336.	1.6	1
316	Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer. Npj Breast Cancer, 2022, 8, 43.	5.2	1
317	Update in treatment of early breast cancer in post-menopausal women. Expert Review of Endocrinology and Metabolism, 2016, 11, 243-252.	2.4	0
318	Reply to L.A. Renfro et al. Journal of Clinical Oncology, 2016, 34, 3950-3950.	1.6	0
319	Response. Journal of the National Cancer Institute, 2018, 110, 1145-1145.	6.3	0
320	Response to: Assessing the risk of bias and publication bias should be integral parts of the systematic review. European Journal of Cancer, 2019, 118, 189.	2.8	0
321	Response to letter to the editor: The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It calls for more careful evaluation. Journal of Surgical Oncology, 2019, 120, 1055-1055.	1.7	0
322	Endpoint selection in HER2-positive early breast cancer. Lancet Oncology, The, 2019, 20, 315-316.	10.7	0
323	Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer. Breast Cancer Research and Treatment, 2020, 182, 259-266.	2.5	0
324	Brostallicin hydrochloride. Drugs of the Future, 2008, 33, 0478.	0.1	0

#	ARTICLE	IF	CITATIONS
325	Gene expression differences between disseminated tumor cells and tumor cells from overt bone metastases in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1040-1040.	1.6	0
326	Impact of renal impairment and granulocyte colony stimulating factor (G-CSF) on bleomycin-induced pneumonitis (bleo lung), febrile neutropenia (FN), and survival in patients (pts) with germ cell tumor (GCT) treated with chemotherapy (chemo).. <i>Journal of Clinical Oncology</i> , 2012, 30, 328-328.	1.6	0
327	Prognostic role of derived neutrophil to lymphocyte ratio (dNLR) in men with metastatic castration resistant prostate cancer (mCRPC) treated in a phase 3 trial (VENICE).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5047-5047.	1.6	0
328	Clinical outcomes of estrogen receptor (ER)-negative and progesterone receptor (PgR)-positive invasive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 567-567.	1.6	0
329	The price of survival: Breast cancer patient preferences about fertility.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9561-9561.	1.6	0
330	Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): A Global Germ Cell Cancer Group (G3) Study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16058-e16058.	1.6	0
331	The impact of multimodality therapy in marginally inoperable soft tissue sarcomas (STS): The Toronto Sarcoma Program Experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11051-11051.	1.6	0
332	Adjuvant chemotherapy and outcome in patients (pts) with nodal (N-) and resection margin negative (R0) pancreatic adenocarcinoma (PC): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4114-4114.	1.6	0
333	Hyperglycemia and survival in solid tumors: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18158-e18158.	1.6	0
334	Post-marketing modifications of drug labels for cancer drugs approved by the US Food and Drug Administration between 2006 and 2016 with and without supporting randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18717-e18717.	1.6	0
335	Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6619-6619.	1.6	0
336	Safety and tolerability of cancer drugs studied in phase 3 randomized controlled trials (RCTs) over the last decade.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6588-6588.	1.6	0
337	Evaluating the value of checkpoint inhibitor therapy using the ASCO and ESMO frameworks.. <i>Journal of Clinical Oncology</i> , 2019, 37, 17-17.	1.6	0
338	FGFR3 mutation as a prognostic indicator in patients with urothelial carcinoma: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 411-411.	1.6	0
339	Cross-trial comparison of taxane versus non-taxane combination chemotherapy regimens for advanced penile cancer (APC): A systematic review.. <i>Journal of Clinical Oncology</i> , 2019, 37, 511-511.	1.6	0
340	Prioritising access to cancer drugs. <i>Lancet Oncology</i> , The, 2022, 23, e1.	10.7	0
341	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	3.7	0